The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy.

Trial Profile

The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs Paricalcitol (Primary)
  • Indications Diabetic nephropathies; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DiaZemp
  • Most Recent Events

    • 12 Apr 2012 Actual patient number is 48 as reported by ClinicalTrials.gov.
    • 12 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Sep 2011 Planned End Date changed from 1 Feb 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top